Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 3M | 891K | 1M | 1M | 1M |
| Gross Profit | 1M | 335K | 348K | 508K | 710K |
| Operating Income | -9M | -13M | -14M | -14M | -7M |
| EBITDA | -8M | -11M | -13M | -14M | -6M |
| Net Income | -9M | -12M | -14M | -14M | -7M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0066
+0.00% today
1Y Change
-40.00%
Window
Jun 23, 2025 → Jun 10, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Polarean Imaging plc (PLLWF) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and down 40.0% across the available one-year price window (Jun 23, 2025 → Jun 10, 2026). Baseline metrics include revenue growth of +246.8%, EPS growth of +87.2%, a dividend yield of 0.0%. What stands out right now is revenue +246.8%, EPS +87.2%, free cash flow +44.8% with operating margin -390.0% and ROIC -91.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PLLWF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PLLWF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PLLWF Max Drawdown
-90.91%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PLLWF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.1M
-10.9% YoY
FY Net Income
-$6.5M
+53.4% YoY
Free Cash Flow
-$5.9M
+54.2% YoY
Revenue Growth
+246.8%
EPS Growth
+87.2%
Gross Margin
16.4%
Net Margin
-373.6%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 3M | 891K | 1M | 1M | 1M |
| Gross Profit | 1M | 335K | 348K | 508K | 710K |
| Operating Income | -9M | -13M | -14M | -14M | -7M |
| EBITDA | -8M | -11M | -13M | -14M | -6M |
| Net Income | -9M | -12M | -14M | -14M | -7M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 12M | 6M | 16M | 29M | 6M |
| Total Assets | 16M | 11M | 23M | 35M | 11M |
| Total Liabilities | 4M | 3M | 3M | 3M | 2M |
| Shareholder Equity | 12M | 8M | 19M | 32M | 9M |
| Total Debt | 504K | 217K | 502K | 490K | 221K |
| Net Debt | -12M | -6M | -16M | -28M | -6M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
6M
+52.7% YoY
Capital Expenditures
66K
+87.9% YoY
Free Cash Flow
6M
+54.2% YoY
Key ratios
Gross Margin
16.4%
Operating Margin
-390.0%
Net Margin
-373.6%
ROE
-74.0%
Debt / Equity
0.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.